Pluri Inc (PLUR) Actualités

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by...

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR...

Form 8-K - Current report

Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply

HAIFA, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR...

Form 8-K - Current report

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

$10 million funding round from U.S. and EU strategic investors, will accelerate growth and empower efficient...

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract

As part of Pluri’s previously announced $4.2 million 3-year contract with the U.S. National Institute of...

Form 8-K - Current report

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

New production process will be developed based on Pluri’s proprietary 3D cell expansion technologyHuman breast...